These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36908896)

  • 21. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic Resonance Imaging in Stable Mild Cognitive Impairment, Prodromal Alzheimer's Disease, and Prodromal Dementia with Lewy Bodies.
    Siddiqui TG; Whitfield T; Praharaju SJ; Sadiq D; Kazmi H; Ben-Joseph A; Walker Z
    Dement Geriatr Cogn Disord; 2020; 49(6):583-588. PubMed ID: 33227783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers.
    Marizzoni M; Ferrari C; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ribaldi F; Rossini PM; Schönknecht P; Salvatore M; Soricelli A; Hensch T; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    J Alzheimers Dis; 2019; 69(1):3-14. PubMed ID: 29914031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
    Dickerson BC; Wolk DA;
    Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
    Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
    J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuronal ER-Signalosome Proteins as Early Biomarkers in Prodromal Alzheimer's Disease Independent of Amyloid-β Production and Tau Phosphorylation.
    Mesa-Herrera F; Marín R; Torrealba E; Santos G; Díaz M
    Front Mol Neurosci; 2022; 15():879146. PubMed ID: 35600079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.
    Lindemer ER; Salat DH; Smith EE; Nguyen K; Fischl B; Greve DN;
    Neurobiol Aging; 2015 Sep; 36(9):2447-57. PubMed ID: 26095760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    Cavedo E; Lista S; Khachaturian Z; Aisen P; Amouyel P; Herholz K; Jack CR; Sperling R; Cummings J; Blennow K; O'Bryant S; Frisoni GB; Khachaturian A; Kivipelto M; Klunk W; Broich K; Andrieu S; de Schotten MT; Mangin JF; Lammertsma AA; Johnson K; Teipel S; Drzezga A; Bokde A; Colliot O; Bakardjian H; Zetterberg H; Dubois B; Vellas B; Schneider LS; Hampel H
    J Prev Alzheimers Dis; 2014 Dec; 1(3):181-202. PubMed ID: 26478889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brainstem Volumetric Integrity in Preclinical and Prodromal Alzheimer's Disease.
    Dutt S; Li Y; Mather M; Nation DA;
    J Alzheimers Dis; 2020; 77(4):1579-1594. PubMed ID: 32925030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease.
    Festoff BW; Sajja RK; van Dreden P; Cucullo L
    J Neuroinflammation; 2016 Aug; 13(1):194. PubMed ID: 27553758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats.
    Souchet B; Audrain M; Gu Y; Lindberg MF; Orefice NS; Rey E; Cartier N; Janel N; Meijer L; Braudeau J
    J Prev Alzheimers Dis; 2022; 9(3):480-490. PubMed ID: 35841249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer's Disease and Correlation with Cerebral Hypoperfusion Pattern.
    Mazzon G; Ajčević M; Cattaruzza T; Menichelli A; Guerriero M; Capitanio S; Pesavento V; Dore F; Sorbi S; Manganotti P; Marini A
    Curr Alzheimer Res; 2019; 16(6):483-494. PubMed ID: 31057108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incident Cerebral Microbleeds Detected by Susceptibility Weight-Imaging Help to Identify Patients with Mild Cognitive Impairment Progressing to Alzheimer's Disease.
    Basselerie H; Bracoud L; Zeestraten E; Bouguen E; Kiyasova V; Pueyo M; Cognard C; Dumas H; Gramada R; Ousset PJ; Vellas B; Bonneville F
    J Alzheimers Dis; 2017; 60(1):253-262. PubMed ID: 28826188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
    Drago V; Babiloni C; Bartrés-Faz D; Caroli A; Bosch B; Hensch T; Didic M; Klafki HW; Pievani M; Jovicich J; Venturi L; Spitzer P; Vecchio F; Schoenknecht P; Wiltfang J; Redolfi A; Forloni G; Blin O; Irving E; Davis C; Hårdemark HG; Frisoni GB
    J Alzheimers Dis; 2011; 26 Suppl 3():159-99. PubMed ID: 21971460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
    Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
    Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classifying cognitive impairment based on the spatial heterogeneity of cerebral blood flow images.
    Shirzadi Z; Stefanovic B; Mutsaerts HJMM; Masellis M; MacIntosh BJ;
    J Magn Reson Imaging; 2019 Sep; 50(3):858-867. PubMed ID: 30666734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.